Filter By Category
Archives
Share on -
ACMUCABTAGENE AUTOLEUCEL
Generic Name: ACMUCABTAGENE AUTOLEUCEL
ABSTRACT -
Acmucabtagene Autoleucel is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy. It involves genetically engineering a patient's own T-cells to recognize and destroy specific cancer cells. The therapy is being investigated for hematological malignancies and potentially solid tumors. It represents a personalized cellular immunotherapy approach.
DOSAGE -
Acmucabtagene Autoleucel is administered as a single intravenous infusion following lymphodepleting chemotherapy. Dosing is patient-specific and based on body weight and clinical protocol. Administered only in certified healthcare facilities capable of managing cytokine release syndrome (CRS) and neurological toxicities.
SIDE EFFECTS –
Reported or potential side effects may include:
- Cytokine release syndrome (CRS)
- Neurotoxicity (ICANS)
- Fatigue
- Fever
- Hypotension
- Infections
- Cytopenias
- Edema
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Severe hypersensitivity reactions
- Anaphylaxis
- Acute infusion reactions
- Difficulty breathing
- Urticaria
DRUG INTERACTIONS–
- Corticosteroids (used to manage CRS)
- Immunosuppressants
- Live vaccines (contraindicated)
- Tocilizumab (used in CRS management)
PREAUTIONS–
- Requires REMS program enrollment.
- Only administered in specialized centers.
- Patients monitored for at least 4 weeks post-infusion.
- Not suitable for active uncontrolled infection.
- Fertility effects not established.
WARNINGS –
- Boxed warning: Cytokine Release Syndrome and Neurological Toxicities.
- Risk of prolonged cytopenias.
- Secondary malignancies including T-cell malignancies have been reported.
- Do not administer live vaccines after therapy.
- Requires long-term follow-up monitoring.
Share on -
. Developed by